Article · 30 Apr 2025
OtherPublished 11 Jul 2016
Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkins lymphoma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Diffuse large B-cell lymphoma is the most common non-Hodgkin’s lymphoma. Although over 50% of patients are cured with first-line therapy that includes an anthracycline, there are a number of patients who require systemic therapy for relapsed or refractory disease. Currently, no drug is approved for this indication. Pixantrone, a novel aza-anthracenedione, was developed to maintain clinical efficacy while minimizing the cardiac toxicity associated with anthracyclines. Initial results of clinical trials demonstrate that pixantrone induces responses in this difficult-to-treat patient population with tolerable side effects. Results of ongoing clinical trials will better define pixantrone’s role in treating diffuse large B-cell lymphoma and help assess its long-term cardiac toxicity.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Investigation.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Anne W Beaven”
- BylineArticles whose byline prints “David Rizzieri”